{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '-', 'If such values do not return to normal/baseline within a period of time judged', 'reasonable by the investigator, the etiology should be identified, and the Sponsor', 'notified.', 'All protocol-required laboratory assessments, as defined in Appendix 2', '(Section 10.2), must be conducted in accordance with the Laboratory Manual', 'and the SoA.', 'If laboratory values from non-protocol specified laboratory assessments performed at', \"the institution's local laboratory require a change in subject management or are\", 'considered clinically significant by the investigator (eg, SAE or AE or dose', 'modification), then the results must be recorded in the source document.', '8.3.', 'Adverse Events, Serious Adverse Events, and Adverse Events of', 'Interest', 'The definitions of an AE, SAE, and AE of Interest can be found in Appendix 3 (Section 10.3).', 'AE will be reported by the subject (or, when appropriate, by a caregiver, surrogate,', \"or the subject's legally authorized representative).\", 'The investigator and any qualified designees are responsible for detecting, documenting, and', 'recording events that meet the definition of an AE, SAE, or AE of Interest.', '8.3.1.', 'Time Period and Frequency for Collecting AE and SAE Information', 'Treatment-emergent adverse events will be collected from the first dose of IP until the end of', 'follow up. Serious adverse events will be collected beginning at the time of consent until the end', 'of follow up. Medical occurrences that begin after obtaining informed consent and before the', 'first dose of IP will be recorded on the Medical History/Current Medical Conditions section of', 'the eCRF and not the AE section.', 'All SAEs will be recorded and reported to the Sponsor or designee immediately upon the site', 'learning of an event and under no circumstance should this exceed 24 hours, as indicated in', 'Appendix 3 (Section 10.3.5). The investigator will submit any updated SAE data to the Sponsor', 'within 24 hours of it being available.', 'Investigators are not obligated to actively seek AEs or SAEs that start after conclusion of the', 'study participation. However, if the investigator learns of any SAE, including a death, at any', 'time after a subject has been discharged from the study, and he/she considers the event to be', 'reasonably related to the IP or study participation, the investigator must promptly notify the', 'Sponsor.', '8.3.2.', 'Method of Detecting AEs and SAEs', 'The method of recording, evaluating, and assessing causality of AE and SAE and the procedures', 'for completing and transmitting SAE reports are provided in Appendix 3 (Section 10.3).', 'Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and', 'non-leading verbal questioning of the subject is the preferred method to inquire about', 'AE occurrences.', '42', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '8.3.3.', 'Follow-up of AEs and SAEs', 'After the initial AE/SAE report, the investigator is required to proactively follow each subject', 'at subsequent visits/contacts. All SAEs and events of interest (defined in Section 10.3) will be', 'followed until resolution, stabilization, the event is otherwise explained, or the subject is lost to', 'follow up (as defined in Section 7.3). Further information on follow-up procedures is given in', 'Appendix 3 (Section 10.3).', '8.3.4.', 'Regulatory Reporting Requirements for SAEs', 'Prompt notification by the investigator to the Sponsor of a SAE is essential so that', 'legal obligations and ethical responsibilities towards the safety of subjects and the', 'safety of the IP under clinical investigation are met.', 'The Sponsor has a legal responsibility to notify both the local regulatory authority', 'and other regulatory agencies about the safety of an IP under clinical investigation.', 'The Sponsor will comply with country-specific regulatory requirements relating to', 'safety reporting to the regulatory authority, Institutional Review Boards', '(IRB)/Independent Ethics Committees (IEC), and investigators.', 'Investigator safety reports must be prepared for SUSAR according to local regulatory', 'requirements and Sponsor policy and forwarded to investigators as necessary.', 'An Investigator who receives an Investigator safety report from the Sponsor', 'describing a SAE or other specific safety information (eg, summary or listing of', 'SAEs) will review and then file it along with the IB. The Investigator will then notify', 'the IRB/IEC, if appropriate according to local requirements.', '8.3.5.', 'Pregnancy', 'Details of all pregnancies will be collected as outlined in Appendix 4 (Section 10.4).', 'If a pregnancy is reported, the investigator should inform the Sponsor within 24 hours', 'of learning of the pregnancy and should follow the procedures outlined in Appendix 4', '(Section 10.4).', 'Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth,', 'congenital anomalies, ectopic pregnancy) are considered SAEs.', '8.3.6.', 'Death Events', 'Timelines for reporting of death events are identical to the requirements for SAE reporting.', '(Section 10.3.5).', '8.3.7.', 'Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as AEs', 'or SAEs', 'CRS exacerbation is an efficacy assessment that is a disease-related outcome not qualifying as an', 'AE unless the investigator considers the CRS exacerbation to have met the definition of an SAE', '(Appendix 3; Section 10.3.2). CRS exacerbation meeting the definition of an SAE will be', 'reported in the appropriate eCRF (Appendix 3; Section 10.3.5). CRS exacerbation not meeting', 'the definition of an SAE should not be reported as an AE. CRS exacerbations, as captured by', '43', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}